RxDoctor Payments Data

Cindy White, NP

Nurse Practitioner · Mount Airy, NCNPI 1942897400

Payments from drug & device makers

$2,212in general payments, 2019–2025

Across 88 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$451
  • Sumitomo Pharma America, Inc.$303
  • Pfizer$255
  • Astellas Pharma US Inc$148
  • Endo USA, Inc.$134
  • Endo Pharmaceuticals Inc.$97
  • plus $826 from 22 others

What the payments were for

  • Travel & lodging$22610%
  • Food & beverage$1,87685%
  • Education$1105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,212 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,326
Medicare patients
373
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron268$177,248
MyrbetriqMirabegron196$97,372
Fesoterodine Fumarate ErFesoterodine Fumarate66$8,393
Estradiol98$6,921
Tolterodine Tartrate ErTolterodine Tartrate69$6,134
Solifenacin Succinate206$5,385
Tamsulosin Hcl701$4,804
Fosfomycin Tromethamine40$3,840
Mirabegron ErMirabegron12$3,491
Methenamine Hippurate62$3,178
Potassium Citrate ErPotassium Citrate40$3,169
Finasteride342$3,116
NitrofurantoinNitrofurantoin Macrocrystal73$2,776
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst129$2,180
Trimethoprim40$2,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$303$177,248268 claims
Astellas Pharma US IncMyrbetriq$148$97,372196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Mount Airy

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →